Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of GAP Stage at Baseline in the INPULSIS Trials
Author:
John Belperio,Christopher Ryerson,Martin Kolb,Luca Richeldi,Joyce Lee,Wibke Stansen,Susanne Stowasser,Venerino Poletti
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.